Impact of Bariatric Surgery on the Pharmacokinetics Parameters of Amoxicillin

• DOI: 10.1007/s11695-018-3591-3
• Publication Date: 2018-11-10T16:56:28Z
• Authors: Marina Becker Sal...; Gilberto De Nucci; Francisco Ney Lemos; Rodrigo Feitosa d...; Andrea Vieira Pon...; Francisco Vagnald...; Natalícia J. Antunes; Gustavo D. Mendes; Demetrius Fernand...; Manoel Odorico de...; Maria Elisabete A...
• Keywords: Gastric bypass surgery

Bariatric surgery leads to several anatomo-physiological modifications that may affect pharmacokinetic parameters and consequently alter the therapeutic effect of drugs, such as antibiotics. The pharmacokinetics of oral amoxicillin after Roux-en-Y gastric bypass (RYGB) surgery is unknown.The objective of this study was to evaluate the impact of bariatric surgery on the pharmacokinetics of amoxicillin.This study was performed as a randomized, open-label, single-dose clinical trial, with two periods of treatment, in which obese subjects (n = 8) received an amoxicillin 500 mg capsule orally before and 2 months after the RYGB surgery. The amoxicillin plasma concentration was determined by liquid chromatography coupled to mass spectrometry (LC-MS/MS).After the surgery, the mean weight loss was 17.03 ± 5.51 kg, and mean body mass index (BMI) decreased from 46.21 ± 2.82 to 38.82 ± 3.32 kg/m2. The mean amoxicillin area under the plasma concentration versus time curve from time zero to the time of the last quantifiable concentration (AUC0-tlast) increased significantly (3.5-fold); the maximum plasma concentration (Cmax) increased 2.8-fold after the bariatric surgery. No correlation was found between amoxicillin absorption, BMI, and weight loss percentage.The alterations observed in the amoxicillin pharmacokinetics suggest that obese subjects included in this trial had a substantially increase in amoxicillin systemic exposure after RYGB surgery. However, despite this increase, its exposure was lower than the values reported for non-obese volunteers.Identifiers: NCT03588273.